Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells

Herein, we developed the first metal-based mitochondrial topoisomerase inhibitors to achieve an effective therapeutic outcome for the therapy of cisplatin-resistant tumour cells.

Automated summary

Researchers have developed the first metal-based mitochondrial topoisomerase inhibitors to effectively treat cisplatin-resistant tumor cells.